Nephrotic Syndrome News and Research

RSS

Nephrotic syndrome is characterized by a set of signs and symptoms including proteinuria, low protein levels in the blood, hypercholesterolemia, hypertriglyceridemia, and edema. It may be caused by various disorders of the kidney, and the management of the condition varies according to the specific case and the cause of the symptoms.

Halpin Foundation-ASN grant advances research in membranous nephropathy

The Halpin Foundation and the American Society of Nephrology (ASN) proudly highlight the research advances in membranous nephropathy made possible by The Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant.

11 Nov 2010

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.

15 Oct 2010

Questcor Pharmaceuticals provides update on sNDA for H.P. Acthar Gel

Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.

9 Sep 2010

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

11 Jun 2010

Bevacizumab increases risk for proteinuria in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment. This conclusion stems from a study of more than 12,000 patients by Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center. Their findings are reported in online June 10 in the Journal of the American Society Nephrology (JASN).

11 Jun 2010

Discovery suggests how toxin-filtering cells go awry

Researchers from Children's Hospital Boston and Brigham and Women's Hospital have identified an important genetic cause of a devastating kidney disease that is the second leading cause of kidney failure in children, according to The NephCure Foundation.

22 Dec 2009

Children with minimal change nephrotic syndrome can be treated with prednisone

A kidney condition that can arise in children and was until recently believed to disappear after puberty may persist into adulthood and cause significant long-term complications, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that better treatment options are needed for children with the disorder, called minimal change nephrotic syndrome.

25 Sep 2009

NIH, NephCure Foundation and University of Michigan support study of nephrotic syndrome

University of Michigan Health System researchers will lead a $10.25 million effort to study rare kidney diseases that cause kidney failure and the need for dialysis.

23 Sep 2009

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

Vermillion issued U.S. patent for method to aid diagnosis of nephrotic syndrome

Vermillion, Inc. has announced that the United States Patent Office (USPTO) has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome, a kidney disorder marked by very high or low levels of protein in the urine, which results in bodily swelling and high cholesterol.

29 Nov 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

How kidneys retain proteins, discard waste

New research may finally settle a decades-old debate about how the kidney keeps valuable blood proteins from harmfully slipping into the urine, a serious health symptom that often precedes kidney failure.

2 Aug 2006

Children who take steroid drugs for nephrotic syndrome do not suffer bone loss

Childhood nephrotic syndrome, which affects 3 out of 100,000 children, is the most common chronic kidney disease in children. Although it does not impair kidney function, it weakens the body's ability to remove water and salt from the blood, and causes swelling in the belly, legs, and around the eyes.

25 Aug 2004